Skip to main content

Table 1 Baseline characteristics placebo and supplement group (Median Q1-Q3, unless stated otherwise)

From: Oxidative damage and inflammation in obese diabetic Emirati subjects supplemented with antioxidants and B-vitamins: a randomized placebo-controlled trail

   Placebo Supplement P value
(n = 50) (n = 50)
Age   51 (42–60) 52 (44–56) 0.964
Male: female (n)   18:32 23:27 0.312
Smoking (n)   2 6  
Duration of diabetes (yrs)   2.0 (1–3) 3 (1–3) 0.258
Previous Hypertension (n)   34 28 0.219
Previous IHD (n)   8 7 0.781
High cholesterol (n)   36 38 0.650
Number of drugs/patient   2.2 2.3 0.849
Treatment of diabetes (n) Diet 2 2 0.059
  Tablet 36 28  
  Insulin 9 18  
  Both 3 2  
Other treatments, n (%)     
ACE inhibitors   13 (26) 12 (24) 0.863
Calcium channel blockers   1 (2) 2 (4) 0.548
B blockers   14 (28) 16 (32) 0.616
aspirin   36 (72) 40 (80) 0.259
Statins   38 (76) 36 (72) 0.773
Body mass index   32 (29–36) 31. (26–35)) 0.278
Fat mass (kg)   36 (28–43) 35 (29–43) 0.683
Waist circumference (cm)   104 (95–115) 100 (95–110) 0.281
Systolic BP (mmHg)   135 (121–145) 136 (120–153) 0.490
Diastolic BP (mmHg)   79 (70–85) 80 (73–86) 0.304
HbAic (%)   7.8 (7.0-9.3) 7.7 (6.4-9.0) 0.780
Total cholesterol (mmol/L)   4.1 (4.0-5.0) 4.3 (3.8-4.9) 0.402
Triglycerides (mmol/L)   1.0 (0.83-1.44) 1.35 (0.75-1.7) 0.335